Kravitz Meryl B, Annadata Vivek, Ilyaev Benjamin, Tong Charles C L, Fastenburg Judd H, Chaskes Mark B
Department of Otolaryngology/Head & Neck Surgery, Zucker School of Medicine, Hofstra University, New York, NY 11040, USA.
Department of Otolaryngology/Head & Neck Surgery, Montefiore Medical Center, New York, NY 10467, USA.
Cancers (Basel). 2024 Dec 24;17(1):4. doi: 10.3390/cancers17010004.
Squamous cell carcinoma is the most common malignancy affecting the sinonasal tract. Local recurrence is the main pattern of treatment failure, affecting nearly half of patients treated for primary sinonasal squamous cell carcinoma (SNSCC). Due to disease rarity and heterogeneity of practices, there are limited guidelines for how to diagnose and care for these patients. This paper reviews current evidence regarding etiology, pathophysiology, diagnosis, prognostic factors, and treatment modalities of recurrent SNSCC (rSNSCC). Currently, salvage surgery offers the only durable approach for eligible patients. These resections often require robust reconstructive options due to prior surgery or radiation. Chemoradiation is offered as an adjuvant or palliative approach when surgery is not a feasible option. Emerging options such as immunotherapy and particle therapy remain an area of ongoing investigation.
鳞状细胞癌是影响鼻窦区域最常见的恶性肿瘤。局部复发是治疗失败的主要模式,几乎影响了一半接受原发性鼻窦鳞状细胞癌(SNSCC)治疗的患者。由于该疾病罕见且治疗方法存在异质性,关于如何诊断和治疗这些患者的指南有限。本文综述了复发性鼻窦鳞状细胞癌(rSNSCC)的病因、病理生理学、诊断、预后因素及治疗方式的现有证据。目前,挽救性手术为符合条件的患者提供了唯一持久的治疗方法。由于先前的手术或放疗,这些切除术通常需要强大的重建方案。当手术不可行时,放化疗可作为辅助或姑息治疗方法。免疫疗法和粒子疗法等新兴治疗方法仍是正在进行研究的领域。
Cancers (Basel). 2024-12-24
Cancers (Basel). 2021-6-7
Auris Nasus Larynx. 2021-2
Arch Otolaryngol Head Neck Surg. 2009-12
Biomedicines. 2022-5-28
J Neurol Surg Rep. 2025-4-25
Int Forum Allergy Rhinol. 2024-11
Oral Oncol. 2024-10
Eur Arch Otorhinolaryngol. 2024-7